In Vivo Activity of QPX7728, an Ultrabroad-Spectrum Beta-Lactamase Inhibitor, in Combination with Beta-Lactams against Carbapenem-Resistant Klebsiella pneumoniae-Reference-Cited by-同舟云学术

In Vivo Activity of QPX7728, an Ultrabroad-Spectrum Beta-Lactamase Inhibitor, in Combination with Beta-Lactams against Carbapenem-Resistant Klebsiella pneumoniae

Published:2020-10-20 Issue:11 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Sabet Mojgan¹,Tarazi Ziad¹,Griffith David C.¹^ORCID

Affiliation:

1. Qpex Biopharma, Inc., San Diego, California, USA

Abstract

Resistance to beta-lactams has created a major clinical issue. QPX7728 is a novel ultrabroad-spectrum cyclic boronic acid beta-lactamase inhibitor with activity against both serine and metallo-beta-lactamases developed to address this resistance for use in combination with beta-lactam antibiotics. The objective of these studies was to evaluate the activity of QPX7728 in combination with multiple beta-lactams against carbapenem-resistant Klebsiella pneumoniae isolates in a neutropenic mouse thigh infection model.

Funder

HHS | Biomedical Advanced Research and Development Authority

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01267-20

Reference37 articles.

1. Clinical characteristics, risk factors, and outcomes of patients hospitalized in the US military health system with carbapenem-resistant Enterobacteriaceae infection

2. The beta lactam antibiotics as an empirical therapy in a developing country: an update on their current status and recommendations to counter the resistance against them;Thakuria B;J Clin Diagn Res,2013

3. Susceptibility patterns and ESBL rates of Escherichia coli from urinary tract infections in Canada and the United States, SMART 2010–2014

4. The Current State of Multidrug-Resistant Gram-Negative Bacilli in North America

5. Association of high mortality with extended–spectrum β-lactamase (ESBL) positive cultures in community acquired infections

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evolving resistance landscape in gram‐negative pathogens: An update on β‐lactam and β‐lactam‐inhibitor treatment combinations for carbapenem‐resistant organisms;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2024-07

2. Therapies in preclinical and in early clinical development for the treatment of urinary tract infections: from pathogens to therapies;Expert Opinion on Investigational Drugs;2024-05-09

3. Metallo-β-lactamases;Metalloenzymes;2024

4. Antibiotic Adjuvants: A Versatile Approach to Combat Antibiotic Resistance;ACS Omega;2023-03-14

5. Efficacy and In Vitro Activity of Novel Antibiotics for Infections With Carbapenem-Resistant Gram-Negative Pathogens;Frontiers in Cellular and Infection Microbiology;2022-05-20